

Dear committee members:

I would like to ask for your consideration of adding Invokana to the formulary for treating my diabetic patients. I have used this Rx extensively since it came out and have found it to be *wonderful new tool in the box* to help my patients get to their A1C goals. I have reviewed the cardiovascular data for this group of drugs and it is quite remarkable that in only a matter of weeks, there seems to be mortality benefits. Invokana's data seems to be very strong for those many patients whom we have already identified with macro vascular heart disease. Very intriguing.

Please, if you could take a look at adding this Rx that I use frequently (and its various combinations with metformin) to the formulary, I would appreciate your consideration.